Eli Lilly & Co. (LLY) Misses Q4 EPS by 1c, Revenue Beats, FY19 EPS Guidance Misses
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Eli Lilly (LLY) PT Raised to $115 at Credit Suisse
February 7, 2019 7:59 AM ESTCredit Suisse analyst Vamil Divan raised the price target on Eli Lilly (NYSE: LLY) to $115.00 (from $112.00) while maintaining a Neutral rating following the company's 4Q earnings report. Overall, 4Q18 was mixed, as revenues beat expectations but EPS missed forecasts by a... More
Eli Lilly (LLY) PT Raised to $143 at Cantor Fitzgerald
February 6, 2019 1:28 PM ESTCantor Fitzgerald analyst Louise Chen raised the price target on Eli Lilly (NYSE: LLY) to $143.00 (from $128.00) while maintaining a Overweight rating.
Chen commented, "Post a modest 4Q18 EPS miss, we maintain our OW rating and increase our 12 month PT to $143... More
